Abstract:Haoqian Chen, 1 Xiao Zheng, 2, 3 Lingjue Li, 1 Lishuxin Huang, 1 Weiwei Huang, 2 Yanbing Ma 2 1 Key Laboratory of Chemistry in Ethnic Medicinal Resources, State Ethnic Affairs Commission & Ministry of Education, School of Ethnic Medicine, Yunnan Minzu University, Kunming, People's Republic of China; 2 Laboratory of Molecular Immunology, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, People's Republic of China; 3 School of Life Sciences, Yunnan University, Kunming, People's Republic of China Correspondence: Lishuxin Huang, Key Laboratory of Chemistry in Ethnic Medicinal Resources, State Ethnic Affairs Commission & Ministry of Education, School of Ethnic Medicine, Yunnan Minzu University, Kunming, 650504, People's Republic of China, Tel/Fax +86 871 6592 6040, Email Yanbing Ma, Laboratory of Molecular Immunology, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 935 Jiaoling Road, Kunming, 650032, People's Republic of China, Tel +86 871 6833 9287, Fax +86 871 6833 4483, Email Background: Peptide-based vaccines have broad application prospects because of their safety, simple preparation, and effectiveness, especially in the development of personalized cancer vaccines, which have shown great advantages. However, the current peptide-based vaccines often require artificial synthesis and intricate delivery technology, which increases the cost and complexity of preparation. Methods: Here, we developed a simple technique for combining a peptide and a delivery system using the natural secretion system of bacteria. Specifically, we biosynthesized an antigenic peptide in bacteria, which was then extracellularly released through the bacterial secretory vesicles, thus simultaneously achieving the biosynthesis and delivery of the peptide. Results: The system utilizes the natural properties of bacterial vesicles to promote antigen uptake and dendritic cell (DC) maturation. Therefore, tumor-specific CD4 + Th1 and CD8 + cytotoxic T lymphocyte (CTL) responses were induced in TC-1 tumor-bearing mice, thereby efficiently suppressing tumor growth. Conclusion: This research promotes innovation and extends the application of peptide-based vaccine biosynthesis technology. Importantly, it provides a new method for personalized cancer immunotherapy that uses screened peptides as antigens in the future. Keywords: tumor immunization, peptide vaccine, outer membrane vesicle, delivery system Immunotherapy is considered a potential cancer treatment strategy, 1 in which therapeutic cancer vaccines are an important factor. 2 The effectiveness of therapeutic cancer vaccines has been demonstrated in a variety of cancer types. At present, the therapeutic cancer vaccine strategy targeting screened personalized neoantigens has gradually shown great application prospects. 3 Enabling the simultaneous display of multiple tumor antigens by linking antigens using a plug-and-play system may be a valuable approach for the development of personalized tumor vaccines against complex and heterogeneous tumor antigens. 4,5 Recently, peptide-based vaccines have received increasing attention in both infectious disease and cancer research fields because of their convenient preparation, high safety, and favorable immunogenicity. Peptide-based vaccines can be intelligently designed to target specific MHC molecules for efficient presentation, thereby enhancing B-cell and T-cell responses. An advantage of peptide-based vaccines is that they are easy to synthesize, eliminating the need for many tedious processes, such as the expression and purification of vaccine antigens and in vitro transcription of nucleic acid vaccines. Peptide-based vaccines can be easily obtained through artificial synthesis, and have high purity. However, although artificially synthesized peptides are convenient, they have a higher cost. In addition, peptide-based vaccines generally require a suitable delivery system to protect and deliver the peptide, which increases the cost and complexity of peptide-based vaccine preparation. Currently, more than 500,000 women are diagnosed with cervical cancer each year, and the disease causes more than 300,000 deaths worldwide. In most cases, high-risk subtypes of human papilloma virus (HPV) are the cause of the disease. However the disease is largely preventable. 6 We have also conducted some previous research on the treatment of this disease and we established a vaccine technology platform based on norovirus virus-like particles (VLPs) displaying personalized antigens. 7 -Abstract Truncated-

Cancer Immunoinformatics: A Promising Era in the Development of Peptide Vaccines for Human Papillomavirus-induced Cervical Cancer

A Comparative Analysis of Computational Strategies in Multi-Epitope Vaccine Design Against Human Papillomavirus and Cervical Cancer

The Role and Development of Peptide Vaccines in Cervical Cancer Treatment

Computational Modeling of Immune Response Triggering Immunogenic Peptide Vaccine Against the Human Papillomaviruses to Induce Immunity Against Cervical Cancer.

Immunomics Datasets and Tools: to Identify Potential Epitope Segments for Designing Chimeric Vaccine Candidate to Cervix Papilloma.

Immunoinformatics Design and In Vivo Immunogenicity Evaluation of a Conserved CTL Multi-Epitope Vaccine Targeting HPV16 E5, E6, and E7 Proteins

Peptide-Based Nanovaccines in the Treatment of Cervical Cancer: A Review of Recent Advances

Designing and immunomolecular analysis of a new broad-spectrum multiepitope vaccine against divergent human papillomavirus types

Exploring the Papillomaviral Proteome to Identify Potential Candidates for a Chimeric Vaccine Against Cervix Papilloma Using Immunomics and Computational Structural Vaccinology.

Integrating immunopeptidome analysis for the design and development of cancer vaccines

Peptide-Based Therapeutic HPV Cancer Vaccine Synthesized via Bacterial Outer Membrane Vesicles

Designing of CD8 + and CD8 + -overlapped CD4 + epitope vaccine by targeting late and early proteins of human papillomavirus.

Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers

Immunoinformatics approach for design novel multi-epitope prophylactic and therapeutic vaccine based on capsid proteins L1 and L2 and oncoproteins E6 and E7 of human papillomavirus 16 and human papillomavirus 18 against cervical cancer

Insights into peptide-based vaccine design for cancer immunotherapy

Computational Identification, Characterization and Validation of Potential Antigenic Peptide Vaccines from Hrhpvs E6 Proteins Using Immunoinformatics and Computational Systems Biology Approaches.

Cancer Immunoinformatics: A New Assistant Tool For Malignant Disease Research

Immunoinformatics Approach for Epitope-Based Vaccine Design: Key Steps for Breast Cancer Vaccine

Designing a therapeutic and prophylactic candidate vaccine against human papillomavirus through vaccinomics approaches

Harnessing the Potential of Plant Expression System towards the Production of Vaccines for the Prevention of Human Papillomavirus and Cervical Cancer

Beyond prevention: in silico designing a one-two punch novel therapeutic vaccine candidate against major oncoproteins of HPV 16, 18, 31, and 45 and subsequent cervical cancer